Overview |
bs-8284r-cy3-100ul |
CRMP2 (Thr514+Ser518) Antibody, Cy3 Conjugated |
IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Mouse, Rat |
Cow, Sheep, Pig, Horse, Chicken |
Specifications |
Cy3 |
Rabbit |
KLH conjugated synthetic phosphopeptide derived from human CRMP2 around the phosphorylation site of Thr514+Ser518 |
Thr514+Ser518 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
1808 |
Cytoplasm |
CRMP2 phospho T514 + S518; CRMP2 phospho T514+S518; CRMP-2phospho Thr514+S518; p-CRMP2Thr514+S518; CRMP2/Dpysl2DRP 2; Collapsin response mediator protein 2; Collapsin response mediator protein hCRMP 2; CRAM; CRMP 2; DHPRP 2; DHPRP2; Dihydr pyrimidinase 2; Dihydropyrimidinase 2; Dihydropyrimidinase like 2; Dihydropyrimidinase like 2 long form;Dihydropyrimidinase related protein 2; DPYL 2; DPYL2; DPYSL 2; DPYSL2; DRP 2; DRP2; Musunc 33; Musunc33; N2A3; TOAD 64; TOAD64; ULIP 2 protein; Ulip2. |
Collapsin response mediator proteins (CRMPs) are cytosolic phosphoproteins involved in neuronal differentiation and axonal guidance. CRMP2 was previously shown to mediate the repulsive effect of Sema3A on axons and to participate in axonal specification. The CRMPs appear to play a complex role in axon growth as well as microtubule dynamics and axon induction. CRMPs localize to the lamellipodia and filopodia of axonal growth cones, suggesting a role in axon guidance. Moreover, CRMP2 is upregulated after axotomy, and appears to increase the formation of axon-type processes from hippocampal neurons. CRMP2 has been reported to bind tubulin dimers directly and modulate microtubule assembly. CRMPs have also been implicated in the pathogenesis of a paraneoplastic neurologic syndrome. Interaction studies have implicated phospholipase D2 (PLD2), the cytosolic tyrosine kinase Fes, and intersectin in CRMP function. Hyperphosphorylation of CRMP2 is an early event in the progression of Alzheimer's disease. |
Application Dilution |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |